Clinical Trial Search

Primary: Number of Participants Whom Received Medihoney Treatment and Were Analyzed Weekly for Skin Changes While Undergoing Radiation Therapy — 15; 15; 15; 15 participants

Primary: Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy…

Primary: Number of Participants Categorized by RTOG Grading Scale — 12; 6; 11; 11 Participants

Primary: Number of Participants With Progression of Radio Therapy Induced Skin Reaction — 35; 33 Participants

Primary: Percent of Women Who Develop Grade 3 or 4 Radiation Dermatitis (as Defined by the Stanford Radiation Dermatitis Scoring System) During a Course of Radiation Therapy — 6…

Primary: Incidence of Early Adverse Skin Reactions (EASRs) — 13; 10; 4; 6 Participants

Primary: Number of Participants With Incidence of High Grade Radiation Dermatitis — 0; 9 Participants — p=0.004

Primary: Mean Radiation Dermatitis Severity Score — 2.02; 1.99 units on a scale — p=0.6555

Primary: Number of Participants With an Adverse Skin Event — 1 Participants

Primary: Radiation Dermatitis — 34; 36 Participants — p=.8872

Primary: Severity of Dermatitis in Radiation Treatment Site in Breast Cancer Patients — 2.6; 3.4 units on a scale — p=0.0077

Primary: Mean Radiation Dermatitis Severity (RDS) Score. Range: 0 (no Dermatitis) - 4 (Violaceous Erythema With Diffuse Desquamation Occurring in Sheets; Patchy Crusting…

Primary: Number of Participants With Grade ≥2 Radiation Dermatitis at 50 Gy (Per Protocol Set) — 3; 9; 6; 18 Participants

Primary: Completion Rate of Use of KeraStat Cream — 10; 7 Participants

Primary: Proportion of Patients Without Grade G2 Skin Toxicity Radiodermatitis at Week 5 — 10; 5; 13; 11 participants

Primary: Radiation Therapy Oncology Group Skin Toxicity Scoring — 0.00; 0.00; 0.09; 0.15 score on a scale

Primary: Rates of Clinically Significant Radiation Dermatitis as Defined as NCI CTCAE Version 5 Grade 2 or Higher — 3; 1 Number of events

Primary: Wound Surface Area Reduction of Radiation Dermatitis Grade 2-3 Wound Size From Baseline to Day 14 (+/- 3 Days) — 10.3; 25.3; 0.5; 4.1 cm^2

Primary: Grade 3 or Higher Adverse Events — 9 Participants

Primary: Mean Maximum Grade of Radiation Dermatitis by Treatment Arm. — 1.2; 1.3 Grade — p=0.18

Primary: Percentage of Participants With Moist Desquamation — 66.7; 43.8 % of participants w/moist desquamation

Primary: Tissue Oxygenation — 62.5 mmHg — p=0.5

Primary: Acute Skin Toxicity Per NCI-CTC v4.0 — 3; 3; 19; 18 Participants

Primary: Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and…

Primary: Percentage of Participants With Specific Grade 2 or Higher Skin Toxicities During the 6-week Skin Treatment Period — 29; 62 percentage of participants

Primary: Number of Accumulated New Skin Lesions at Month 3 — 65; 103 new skin lesions — p=0.0120

Primary: Mean Temperature Change- Skin Evaluation on Leg With Device — 6.21 degrees

Primary: Photoallergic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score During Challenge Phase - All Treated Subjects — 325; 24; 343; 6 Test site

Primary: 2-year Local Recurrence Rate (LRR)/Incidence of Local Recurrence — 10 percentage of patients with LR

Primary: Dose-limiting Toxicity (DLT) — 0; 0; 0; 0 Participants